Autori: Weichenthal Michael
| Naslov | Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe (Article) |
| Autori | Weichenthal Michael ... Kandolf Lidija O ... (broj koautora 22) |
| Info | CANCERS, (2024), vol. 16 br. 21, str. - |
| Projekat | Merck Sharp Dohme LLC; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study (Meeting Abstract) |
| Autori | Asher Nethanel Mohr Peter Ellebaek Eva Bender Marc Mangana Joanna Kandolf Lidija O Gavrilova Iva Ascierto Paolo Antonio Gogas Helen Rutkowski Piotr Schadendorf Dirk Bastholt Lars Weichenthal Michael |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2024), vol. 42 br. 16, Suppl. S, str. - |
| Ispravka | ISI/Web of Science Elečas Rang časopisa |
| Naslov | Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe (Meeting Abstract) |
| Autori | Weichenthal Michael ... Kandolf-Sekulovic Lidija O ... (broj koautora 20) |
| Info | ANNALS OF ONCOLOGY, (2022), vol. 33 br. 7, Suppl. 7, str. S931-S931 |
| Projekat | Novartis AG; Merck Co., Inc.; Bristol Myers Squibb |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. (Meeting Abstract) |
| Autori | Weichenthal Michael ... Kandolf-Sekulovic Lidija O ... (broj koautora 20) |
| Info | JOURNAL OF CLINICAL ONCOLOGY, (2022), vol. 40 br. 16, Suppl. S, str. - |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
